AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Results of Operations and Financial Condition

Item2.02.

On May 11, 2017, Aytu BioScience, Inc. issued a press release
announcing its financial results for the fiscal third quarter
ended March 31, 2017. A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated herein in its entirety
by reference.

The information in this Item 2.02 (including Exhibit 99.1) shall
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

(d) Exhibits

About AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU)

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company also markets Primsol (trimethoprim hydrochloride), a trimethoprim-only oral solution for urinary tract infections. The Company’s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men.

AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Recent Trading Information

AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) closed its last trading session down -0.020 at 0.730 with 37,390 shares trading hands.